Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19044731 | METHOD OF SYNTHESIZING TESTOSTERONE-BASED THIAZOLIDINONE DERIVATIVES | February 2025 | May 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18820993 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18832297 | PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI- COMPONENT MATERIAL | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18832315 | PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6 COMPRISING FISHING NETS | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18745710 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | June 2024 | September 2025 | Abandon | 15 | 2 | 0 | No | No |
| 18655985 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | May 2024 | February 2026 | Allow | 21 | 1 | 0 | No | No |
| 18645972 | CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT | April 2024 | July 2024 | Allow | 3 | 1 | 0 | No | No |
| 18611685 | 8-((4-HYDROXY-3-METHOXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18592020 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | February 2024 | March 2026 | Abandon | 24 | 1 | 0 | No | No |
| 18586019 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | February 2024 | November 2025 | Allow | 21 | 1 | 0 | No | No |
| 18584672 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | February 2024 | February 2025 | Allow | 12 | 1 | 0 | No | No |
| 18584177 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18581677 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | February 2024 | February 2026 | Allow | 23 | 1 | 0 | No | No |
| 18439695 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | February 2024 | December 2025 | Allow | 22 | 1 | 1 | No | No |
| 18432727 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | February 2024 | January 2026 | Abandon | 23 | 1 | 0 | No | No |
| 18414104 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | January 2024 | January 2026 | Abandon | 24 | 0 | 1 | No | No |
| 18411439 | HETEROCYCLIC COMPOUNDS AND RELATED METHODS | January 2024 | September 2025 | Allow | 20 | 1 | 0 | No | No |
| 18405657 | NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | January 2024 | December 2025 | Allow | 23 | 2 | 0 | No | No |
| 18391693 | REDOX ACTIVE MATERIALS, PROCESSES AND USES THEREOF | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18544956 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | December 2023 | July 2025 | Allow | 19 | 2 | 0 | No | No |
| 18542913 | CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3, 4-TETRAHYDROCYCLO-PENTA [B]INDOL-3-YL)ACETIC ACID(COMPOUND1) FOR USE IN SIPI RECEPTOR-ASSOCIATED DISORDERS | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18533894 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | December 2023 | April 2024 | Allow | 4 | 2 | 0 | No | No |
| 18530405 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | December 2023 | July 2025 | Allow | 20 | 2 | 1 | No | No |
| 18529334 | COMPOUNDS, DEVICES, AND USES THEREOF | December 2023 | September 2025 | Allow | 22 | 2 | 1 | No | No |
| 18514959 | INHIBITORS OF LRRK2 KINASE | November 2023 | June 2025 | Allow | 18 | 2 | 0 | No | No |
| 18513229 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | November 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18389574 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOWE SYNDROME | November 2023 | January 2025 | Allow | 15 | 2 | 0 | No | No |
| 18507013 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | November 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18385586 | 8-(4-nitroxybenzylideneamino)naphthalene-1,3-disulfonic acid AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18385808 | 8-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18495845 | Oral Formulation of Clonidine and Midazolam for Sedation in Dental Procedures | October 2023 | July 2024 | Allow | 9 | 0 | 0 | No | No |
| 18493421 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | October 2023 | September 2025 | Allow | 22 | 2 | 1 | No | No |
| 18382896 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | October 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18490596 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | October 2023 | November 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18489303 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM | October 2023 | July 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18486759 | ANTI-VIRAL COMPOUNDS | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18368576 | FLUORESCENT MATERIAL CONTAINING THIOPHENE SULFONE-OLEFIN STRUCTURAL UNIT AND PREPARATION METHOD THEREOF | September 2023 | March 2026 | Allow | 30 | 1 | 0 | No | No |
| 18243771 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18463407 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | September 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18462488 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18451918 | Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors | August 2023 | November 2025 | Allow | 27 | 2 | 1 | No | No |
| 18448497 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | August 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18363933 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | August 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18225589 | Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes) | July 2023 | February 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18328865 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | June 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18255969 | SYNTHESIS OF STRUCTURAL ANALOGS OF LARGAZOLE AND ASSOCIATED COMPOUNDS | June 2023 | October 2024 | Allow | 16 | 2 | 0 | No | No |
| 18039129 | THERAPEUTIC AGENT FOR SHORT TEAR BREAKUP TIME-TYPE DRY EYE AND EYE DROPS CONTAINING SAME | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18323510 | Heterocyclic Adenosine Receptor Antagonists | May 2023 | November 2024 | Allow | 18 | 2 | 0 | No | No |
| 18196459 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18252695 | IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS | May 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18445155 | Ibogaine-related compounds and corresponding methods | May 2023 | July 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18309998 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | May 2023 | March 2026 | Allow | 35 | 2 | 0 | No | No |
| 18250893 | COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR PROMOTING MUSCLE GROWTH | April 2023 | March 2026 | Allow | 34 | 2 | 0 | No | No |
| 18140348 | BENZAZEPINE DERIVATIVES | April 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18307181 | RIP1K INHIBITORS | April 2023 | January 2025 | Allow | 21 | 2 | 0 | No | No |
| 18135898 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | April 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18135499 | MEDICAMENT FOR TREATING COUGH | April 2023 | November 2024 | Allow | 19 | 1 | 1 | No | No |
| 18301742 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | April 2023 | October 2023 | Allow | 6 | 1 | 0 | No | No |
| 18300350 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | April 2023 | April 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18299299 | PROCESS FOR THE PREPARATION OF 1-METHYL-6-[6-R2-5-METHYL-8-(METHYLAMINO)-4-[ (3AS,6AS)-5-METHYL-2,3,3A,4,6,6A-HEXAHYDROPYRROLO[2,3-C]PYRROL-1-YL]-9H-PYRIDO[2,3-B]INDOL-3-YL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID HYDROCHLORIDE | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18298825 | AGENT FOR ELEVATING NITRIC OXIDE CONCENTRATION | April 2023 | August 2025 | Allow | 28 | 0 | 0 | No | No |
| 18128603 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | March 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18028840 | CRYSTAL FORM OF PYRROLO HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18126953 | COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18028578 | MACROCYCLIC COMPOUND | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18026309 | TYK2 INHIBITORS AND USES THEREOF | March 2023 | March 2026 | Allow | 36 | 1 | 0 | No | No |
| 18180997 | PROCESS FOR PREPARING LEVOKETOCONAZOLE | March 2023 | June 2023 | Allow | 3 | 1 | 0 | No | No |
| 18119321 | METHODS OF TREATMENT | March 2023 | August 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18024592 | CELL GLYCOCALYX PROTECTION EFFECT OF ANISODAMINE | March 2023 | February 2026 | Allow | 36 | 2 | 0 | Yes | No |
| 18114043 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | February 2023 | August 2025 | Allow | 29 | 2 | 0 | No | Yes |
| 18041743 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | February 2023 | February 2026 | Allow | 36 | 2 | 0 | No | No |
| 18164974 | Antiviral Pyrazolopiridinone Compounds | February 2023 | February 2025 | Allow | 24 | 1 | 0 | No | No |
| 18162432 | PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDS | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18007054 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | January 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18006927 | STRUCTURAL ANALOGUES OF METHYLPHENIDATE AS PARKINSON'S DISEASE-MODIFYING AGENTS | January 2023 | January 2026 | Allow | 36 | 2 | 0 | No | No |
| 18095621 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | January 2023 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18149696 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | January 2023 | September 2025 | Allow | 33 | 4 | 1 | Yes | No |
| 18003454 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18087338 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | December 2022 | August 2024 | Allow | 20 | 1 | 0 | No | No |
| 18086076 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | December 2022 | June 2025 | Allow | 30 | 2 | 0 | No | No |
| 18078511 | Charged Ion Channel Blockers and Methods for Use | December 2022 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 18062896 | SUBSTITUTED AMINO-PYRIMIDINES | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18000684 | AMINOPYRIDINE COMPOUND | December 2022 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 18073897 | METHODS OF TREATING PATIENTS SUFFERING FROM BRAIN INJURY AND METHODS OF INCREASING THE VALUE OF THE EXTENDED GLASGOW OUTCOME SCALE OF PATIENTS SUFFERING FROM BRAIN INJURY | December 2022 | August 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 18000632 | DUAL KINASE-BROMODOMAIN INHIBITORS | December 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18059838 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | November 2022 | November 2024 | Allow | 23 | 1 | 1 | No | No |
| 17991899 | SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT | November 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 17992371 | Antifibrotic Compounds And Related Methods | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17999104 | COMPOSITIONS AND METHODS OF TREATMENT WITH GLUTATHIONE | November 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 17989237 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | November 2022 | February 2024 | Allow | 15 | 0 | 0 | No | No |
| 17988366 | Aceclidine Derivatives, Compositions Thereof and Methods of Use Thereof | November 2022 | August 2024 | Allow | 21 | 3 | 0 | No | No |
| 17978696 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 17977371 | PHARMACEUTICAL COMPOSITIONS AND METHODS | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17975623 | APPLICATION OF ANLE138B IN DRUG FOR IMPROVING DIET-INDUCED INSULIN RESISTANCE | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17973710 | USE OF ERGOTHIONEINE FOR EXTENDING LIFESPAN OR IMPROVING HEALTHSPAN | October 2022 | September 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17971865 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | October 2022 | November 2023 | Allow | 12 | 0 | 0 | No | No |
| 17967301 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | October 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 17967308 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | October 2022 | May 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17918607 | Synthesis of Vinylic Protected Alcohol Intermediates | October 2022 | June 2025 | Allow | 32 | 1 | 0 | No | No |
| 17995886 | PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDS | October 2022 | December 2025 | Allow | 38 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COLEMAN, BRENDA LIBBY.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner COLEMAN, BRENDA LIBBY works in Art Unit 1624 and has examined 2,090 patent applications in our dataset. With an allowance rate of 72.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner COLEMAN, BRENDA LIBBY's allowance rate of 72.1% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COLEMAN, BRENDA LIBBY receive 1.61 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by COLEMAN, BRENDA LIBBY is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +16.8% benefit to allowance rate for applications examined by COLEMAN, BRENDA LIBBY. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 37.3% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 64.8% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 91.4% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 86.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.5% are granted (fully or in part). This grant rate is in the 52% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.